A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia

BJU International

Volumn 91, Issue 1, 2003, Pages 41-44

  Kirby, Roger S ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

1 antagonist; BPH; Doxazosin; Gastrointestinal therapeutic system; LUTS; Tamsulosin

Indexed keywords

DOXAZOSIN; TAMSULOSIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; RHINITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; URINE FLOW RATE; VERTIGO; BLOOD PRESSURE; CONTROLLED RELEASE FORMULATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DOXAZOSIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0037232329     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.03077.x     Document Type: Article

References (19)

1. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-66
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
3. Debruyne F, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169-75
4. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320
5. Kirby R, Andersson KE, Lepor H, Steers WD. Alpha(1)-adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 2000; 3: 76-83
6. Christensen M, Bendix Holme J, Rasmussen P et al. Doxazosin treatment in patients with prostatic obstruction. Scand J Urol Nephrol 1993; 27: 39-44
7. Janknegt R, Chapple C. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993; 24: 319-26
8. Bendix Holme J, Christensen MM, Rasmussen PC et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol 1994; 28: 77-82
9. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
10. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo- controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
11. Chapple C. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia. rationale and clinical experience. Eur Urol 1996; 29: 129-44
12. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-9
13. Gratzke P, Kirby R. Doxazosin GITS and doxazosin standard in patients with benign prostatic hyperplasia: Double blind trial of efficacy and tolerability. Fortschritte der Medizin 2000; November: 83-93
14. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200
15. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 375-86
16. Guthrie R. Doxazosin for benign prostatic hyperplasia in primary care. Clin Ther 1997; 19: 1269-77
17. Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. Int J Urol 1999; 6: 346-54
18. 1c-adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
19. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 145-54